Immunoglobulin News and Research

RSS

Researchers explore potential role of TARM1 protein in pathogenesis of rheumatoid arthritis

TARM1 is a receptor protein whose role in the functioning of the immune system is unknown. In a new study, scientists from Japan have explored the potential role of TARM1 in the pathogenesis of rheumatoid arthritis by analyzing mouse models.

17 Mar 2021

Living with a COVID-19 case brings worse symptoms and stronger antibody response

This study suggests that high virus exposure levels contribute to greater disease severity and stronger antibody responses. The observations from this study are published on the medRxiv preprint server.

17 Mar 2021

Salivary IgG to SARS-CoV-2 after mild COVID-19

A team of researchers based in Stockholm, Sweden, has demonstrated that individuals exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have antibodies for the disease up to nine months after acquiring the disease, even if they displayed only mild symptoms.

16 Mar 2021

Saliva-based testing as a method for monitoring population immunity to SARS-CoV-2 infection

Researchers in the United States have shown that saliva-based sampling could serve as an accurate and non-invasive alternative to blood sampling for monitoring people’s antibody responses following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or vaccination against the virus.

16 Mar 2021

Why does convalescent plasma therapy for severe COVID-19 show mixed success?

A surprising new preprint, released on the medRxiv* server, suggests that the beneficial effects of convalescent plasma (CP) in this disease stem not only from the presence of neutralizing antibodies, but also the immunomodulatory effects of this plasma that shapes the host immune response.

15 Mar 2021

Study maps crucial component of long-term immune response to SARS-CoV-2

Researchers in the United States have found that protective antibodies generated against the original strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)– the agent that causes coronavirus disease 2019 (COVID-19) – also protect against viral variants.

14 Mar 2021

Could horse-derived antibodies promote immunity against SARS-CoV-2 infection?

Researchers based in India have demonstrated that horses inoculated with an inactivated dosage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are able to produce large amounts of strong antibodies that can neutralize multiple variants

12 Mar 2021

Single-dose vaccines may provide sufficient immunization for individuals previously infected with SARS-CoV-2

A group of researchers based at the Papa Giovanni XXIII hospital in Italy have submitted evidence to suggest that individuals previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may adequately benefit from a single dose of mRNA vaccine, rather than requiring the current two-vaccine regimen.

12 Mar 2021

An overview of the BNT162b2 COVID-19 vaccine by Pfizer-BioNTech

In a study published in the journal Drugs, a researcher tackled the approval of Pfizer-BioNTech’s COVID-19 vaccine, which has now been used in many countries.

12 Mar 2021

Impact of type I interferon (IFN) autoantibodies in critical COVID-19

A new preprint discusses the pathogenesis of this critical COVID-19 with reference to autoimmune phenomena involving the key antiviral type I interferon pathway.

12 Mar 2021

Delaying second dose of Pfizer-BioNTech SARS-CoV-2 vaccine may be feasible in some cases

Researchers in Spain have conducted the most extensive study to date investigating the effectiveness of vaccinating healthcare workers with a single dose of the Pfizer-BioNTech vaccine to protect against coronavirus disease 2019 (COVID-19).

11 Mar 2021

People previously infected with SARS-CoV-2 may achieve immunity after one mRNA vaccine dose, finds study

A team of researchers led by Thomas W. McDade of Northwestern University suggests people who were previously infected with SARS-CoV-2, the causative agent of COVID-19, may require only one dose of the mRNA vaccine to obtain immunity.

11 Mar 2021

Researchers develop assay for qualitative assessment of SARS-CoV-2 neutralizing antibodies

To address the need for a high-quality neutralization assay against SARS-CoV-2, researchers from the NIAID modified and optimized a previously established fluorescence reduction neutralization assay (FRNA) to provide a quantitative assessment of a large number of infected cells through the use of a high-content imaging system.

11 Mar 2021

South African SARS-CoV-2 variant most problematic for BNT-162b2 vaccine

Researchers from Germany and the US investigated the efficacy of neutralizing antibodies against newer variants using serum and saliva samples obtained from groups of infected, vaccinated (with Pfizer BNT-162b2), and uninfected individuals. The researchers started this study to uncover vaccine-induced immune response and show the efficiency of antibody binding and neutralization in SARS-CoV-2 variants.

10 Mar 2021

Pfizer COVID-19 vaccine elicits antibodies in blood and breastmilk simultaneously, finds study

A new study adds to the sum of knowledge around this issue, showing a highly synchronized and rapid development of an antibody response in breast milk and serum, which reached stable levels around two weeks after the second dose of the vaccine was administered.

10 Mar 2021

Study reveals novel approach to reduce the risk of thrombosis by using IgM antibodies

Thrombotic occlusion of blood vessels, which leads to myocardial infarctions, strokes and venous thromboembolisms, is the major cause of death in the western hemisphere.

9 Mar 2021

Two doses of Pfizer-BioNTech SARS-CoV-2 vaccine induce humoral protection against U.K. and S.A. variants

Researchers at the Pitié Salpêtrière Hospital, Department of Virology, Paris, France determined that in BNT162b2-vaccinated participants who received two doses, their sera harbored at least a neutralizing titer against the three SARS-CoV-2 variants.

8 Mar 2021

Researchers identify new molecular mechanisms in chronic skin inflammation

Frequently occurring chronic skin inflammation like in atopic dermatitis (AD or neurodermatitis) and psoriasis have different causes such as genetic predisposition, stress or allergens.

5 Mar 2021

One dose of SARS-CoV-2 vaccine candidate boosts neutralizing antibody response in COVID-19 convalescents

A new study details the results from a single dose of the FINLAY FR 1A recombinant dimeric receptor-binding domain (RBD) base vaccine during a phase I clinical trial with 30 COVID-19 convalescents to test its capacity for boosting natural immunity.

5 Mar 2021

Identification of neutralizing IFNL3 autoantibodies in severe COVID-19 cases

Scientists have recently developed a novel alternative molecular display technology called Molecular Indexing of Proteins by Self Assembly (MIPSA). Their research explains how this technology overcomes the critical disadvantages of PLATO and other full-length protein array technologies.

5 Mar 2021

Immunoglobulin News and Research

Researchers explore potential role of TARM1 protein in pathogenesis of rheumatoid arthritis

Living with a COVID-19 case brings worse symptoms and stronger antibody response

Salivary IgG to SARS-CoV-2 after mild COVID-19

Saliva-based testing as a method for monitoring population immunity to SARS-CoV-2 infection

Why does convalescent plasma therapy for severe COVID-19 show mixed success?

Study maps crucial component of long-term immune response to SARS-CoV-2

Could horse-derived antibodies promote immunity against SARS-CoV-2 infection?

Single-dose vaccines may provide sufficient immunization for individuals previously infected with SARS-CoV-2

An overview of the BNT162b2 COVID-19 vaccine by Pfizer-BioNTech

Impact of type I interferon (IFN) autoantibodies in critical COVID-19

Delaying second dose of Pfizer-BioNTech SARS-CoV-2 vaccine may be feasible in some cases

People previously infected with SARS-CoV-2 may achieve immunity after one mRNA vaccine dose, finds study

Researchers develop assay for qualitative assessment of SARS-CoV-2 neutralizing antibodies

South African SARS-CoV-2 variant most problematic for BNT-162b2 vaccine

Pfizer COVID-19 vaccine elicits antibodies in blood and breastmilk simultaneously, finds study

Study reveals novel approach to reduce the risk of thrombosis by using IgM antibodies

Two doses of Pfizer-BioNTech SARS-CoV-2 vaccine induce humoral protection against U.K. and S.A. variants

Researchers identify new molecular mechanisms in chronic skin inflammation

One dose of SARS-CoV-2 vaccine candidate boosts neutralizing antibody response in COVID-19 convalescents

Identification of neutralizing IFNL3 autoantibodies in severe COVID-19 cases

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News